share_log

Brookline Capital Initiates Coverage On Immunic With Buy Rating, Announces Price Target of $10

Moomoo 24/7 ·  Apr 5 04:59

Brookline Capital analyst Tyler Bussian initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Target of $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment